treatment with a glucagon like peptide-1 receptor agonist or insulin, chronic liver diseases other than NAFLD, alcohol consumption (daily intake >30 g for men and >20 g for women), or malignancies. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.